These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 9462667)

  • 21. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance.
    Fu L; Cheng YC
    Biochem Pharmacol; 1998 May; 55(10):1567-72. PubMed ID: 9633992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation.
    Bock CT; Tillmann HL; Torresi J; Klempnauer J; Locarnini S; Manns MP; Trautwein C
    Gastroenterology; 2002 Feb; 122(2):264-73. PubMed ID: 11832441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
    Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
    Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.
    Sun J; Wang Z; Ma S; Zeng G; Zhou Z; Luo K; Hou J
    J Med Virol; 2005 Mar; 75(3):391-8. PubMed ID: 15648063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants.
    Parekh S; Zoulim F; Ahn SH; Tsai A; Li J; Kawai S; Khan N; Trépo C; Wands J; Tong S
    J Virol; 2003 Jun; 77(12):6601-12. PubMed ID: 12767980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-spliced defective hepatitis B virus genome derived from hepatocellular carcinoma tissue enhanced replication of full-length virus.
    Ma ZM; Lin X; Wang YX; Tian XC; Xie YH; Wen YM
    J Med Virol; 2009 Feb; 81(2):230-7. PubMed ID: 19107969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of famciclovir in the treatment of lamivudine resistance related to an atypical hepatitis B virus mutant.
    Tang S; Ho SK; Moniri K; Lai KN; Chan TM
    Transplantation; 2002 Jan; 73(1):148-51. PubMed ID: 11792996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of small interfering RNA and lamivudine on inhibition of human B virus replication in HepG2.2.15 cells.
    Li GQ; Xu WZ; Wang JX; Deng WW; Li D; Gu HX
    World J Gastroenterol; 2007 Apr; 13(16):2324-7. PubMed ID: 17511031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation.
    Tillmann HL; Trautwein C; Bock T; Böker KH; Jäckel E; Glowienka M; Oldhafer K; Bruns I; Gauthier J; Condreay LD; Raab HR; Manns MP
    Hepatology; 1999 Jul; 30(1):244-56. PubMed ID: 10385663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine.
    King RW; Ladner SK; Miller TJ; Zaifert K; Perni RB; Conway SC; Otto MJ
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3179-86. PubMed ID: 9835512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The mechanism of natural occurrence of two closely linked HBV precore predominant mutations.
    Yuan TT; Faruqi A; Shih JW; Shih C
    Virology; 1995 Aug; 211(1):144-56. PubMed ID: 7645207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
    Zhu Y; Curtis M; Borroto-Esoda K
    Antivir Chem Chemother; 2011 Aug; 22(1):13-22. PubMed ID: 21860069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
    Ohishi W; Shirakawa H; Kawakami Y; Kimura S; Kamiyasu M; Tazuma S; Nakanishi T; Chayama K
    J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
    J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation.
    Ji D; Liu Y; Li L; Xu Z; Si LL; Dai JZ; Li X; Wang L; Yao Z; Xin SJ; Chen GF; Xu D
    J Clin Virol; 2012 May; 54(1):66-72. PubMed ID: 22398037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
    Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
    J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphorothioate di- and trinucleotides as a novel class of anti-hepatitis B virus agents.
    Iyer RP; Jin Y; Roland A; Morrey JD; Mounir S; Korba B
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2199-205. PubMed ID: 15155222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure.
    Günther S; von Breunig F; Santantonio T; Jung MC; Gaeta GB; Fischer L; Sterneck M; Will H
    J Hepatol; 1999 May; 30(5):749-54. PubMed ID: 10365797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Wild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidine.
    Halvas EK; Svarovskaia ES; Freed EO; Pathak VK
    J Virol; 2000 Jul; 74(14):6669-74. PubMed ID: 10864683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.